| __timestamp | Ligand Pharmaceuticals Incorporated | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9136000 | 16606000 |
| Thursday, January 1, 2015 | 5807000 | 21497000 |
| Friday, January 1, 2016 | 5571000 | 25462000 |
| Sunday, January 1, 2017 | 5366000 | 28195000 |
| Monday, January 1, 2018 | 6337000 | 33078000 |
| Tuesday, January 1, 2019 | 11347000 | 36523000 |
| Wednesday, January 1, 2020 | 30419000 | 41455000 |
| Friday, January 1, 2021 | 62176000 | 74400000 |
| Saturday, January 1, 2022 | 52827000 | 101582000 |
| Sunday, January 1, 2023 | 35049000 | 112903000 |
Unleashing insights
In the ever-evolving landscape of biotechnology, understanding cost dynamics is crucial. From 2014 to 2023, Veracyte, Inc. and Ligand Pharmaceuticals Incorporated have shown distinct trajectories in their cost of revenue. Veracyte's cost of revenue surged by approximately 580%, peaking at over $112 million in 2023. This reflects its aggressive expansion and scaling efforts. In contrast, Ligand Pharmaceuticals experienced a more modest increase of around 280%, with a peak in 2021 at $62 million, followed by a decline. This divergence highlights Veracyte's rapid growth strategy compared to Ligand's more stable approach. The data underscores the importance of strategic financial management in the biotech sector, where cost efficiency can significantly impact competitive positioning. As the industry continues to innovate, these trends offer valuable insights into the financial health and strategic priorities of these companies.
Analyzing Cost of Revenue: Eli Lilly and Company and Veracyte, Inc.
Cost of Revenue: Key Insights for Eli Lilly and Company and Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for AstraZeneca PLC and Veracyte, Inc.
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Veracyte, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for Biogen Inc. and Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Veracyte, Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Veracyte, Inc.'s Expenses
Cost of Revenue Trends: Vericel Corporation vs Ligand Pharmaceuticals Incorporated
Cost Insights: Breaking Down Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc.'s Expenses